Summary
EV-302 was a phase 3 randomised controlled trial comparing enfortumab vedotin plus pembrolizumab (dual immunotherapy) to chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer. This report presents patient-reported outcome data from that trial, examining quality of life and symptom burden across treatment arms. The findings appear to contribute to the evidence base on tolerability and patient experience with novel immunotherapy combinations versus conventional chemotherapy in this setting.
UK applicability
Findings are directly applicable to UK clinical practice, as immunotherapy combinations are increasingly adopted in National Health Service oncology protocols for urothelial cancer. The patient-reported outcomes data may inform shared decision-making and treatment selection in UK cancer centres.
Key measures
Patient-reported outcomes including quality of life, symptom severity, and functional assessment; comparison between combination immunotherapy and standard chemotherapy regimens
Outcomes reported
The study compared patient-reported outcomes (PROs) between enfortumab vedotin plus pembrolizumab and chemotherapy in patients with untreated locally advanced or metastatic urothelial cancer. PRO measures likely included quality of life, symptom burden, and functional status assessed via validated questionnaires.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.